Name | Title | Contact Details |
---|
Genocea is harnessing the power of T cell immunity to develop the next generation of vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but are difficult to target using traditional discovery methods. Genocea is able to identify protective T cell antigens in humans using ATLAS(TM), its proprietary technology platform, potentially enabling vaccines and immunotherapies to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy.
northcoast medical is a Morgan Hill, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Access Bio Inc is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
C4 Therapeutics is an early stage a drug discovery company whose mission is to harness targeted protein degradation to develop therapeutics for a broad range of diseases. The centerpiece of our approach is the Degronimid® platform, which enables highly selective small molecule binders to target disease causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system.
Certus International Inc is a Bedford, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.